Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.

Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.

Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.

Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.

Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.

Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.

Syntara shares fell 1% in afternoon trade on Friday.